| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 3.6K | 15.9% |
| Total Income | 3.7K | 9.6% |
| Expenditure | 3.1K | 10.5% |
| PBT | 537.32 | 4.7% |
| Net Profit | 444.62 | 4.7% |
| OPM | 23.72% | 1.53pp |
| NPM | 12.18% | 0.57pp |
| EPS | 10.62 | 3.1% |
Mankind Pharma Reports 24.5% Revenue Growth in Q1FY26 with EBITDA Margin at 23.8%
31 Jul 2025 · 31 Jul 2025, 06:02 pm
Summary
Mankind Pharma, India’s fourth largest pharmaceutical Company, has announced its financial results for the first quarter ended 30 June 2025. The company's revenue grew by 24.5% with EBITDA margins at 23.8%. The growth was led by continued outperformance in Chronic, strong growth in Consumer segment and BSV consolidation. The company also announced an interim dividend of Rs 1 per share.
Key Highlights
- 1
Revenue from Operations at INR 3,570 Cr, up by 24.5% YoY
- 2
Domestic revenue at INR 3,101 Cr, up 18.9%, Exports at INR 469 Cr, up 81.1% YoY
- 3
EBITDA margin of 23.8% up by 20 bps YoY and PAT margin of 12.5%
- 4
Diluted EPS of INR 10.6 down by 20.1% YoY (FV Re.1)
- 5
Domestic revenue increased by 18.9% YoY driven by steady growth in base business and BSV consolidation
- 6
Consumer Healthcare Business revenue growth of 15.0% YoY in Q1FY26
- 7
Exports revenue growth of 81.1% YoY primarily due to consolidation of BSV supported by growth in base business
Management Comments
Mr. Rajeev Juneja — Vice Chairman & Managing Director
Mankind’s revenue grew by 24.5% with EBITDA margins at 23.8% in QIFY26 led by continued 1.4x outperformance in Chronic, strong growth in Consumer segment and BSV consolidation. Visible encouraging trends with 1.8x volume growth to IPM led by outperformance in Anti-infectives & Respiratory segment - apart from continued outperformance in Cardiology and Anti Diabetics. BSV growth initiatives are making steady progress and we remain confident of delivering healthy performance this year onwards.
Informational and educational content only. Not investment advice.